KRON Share Price Performance
US$0.88
-0.15 (-14.56%)
Price US$0.88
Share PriceUS$0.88
KRON Community Narratives
There are no narratives available yet.
Recent KRON News & Updates
No updates
Kronos Bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.06
- Gross Margin
- 100.00%
- Net Profit Margin
- -701.53%
- Debt/Equity Ratio
- 0%
Kronos Bio, Inc. Competitors
About KRON
- Founded
- 2017
- Employees
- 8
- CEO
- WebsiteView website
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.
U.S. Market Performance
- 7 Days: 2.3%
- 3 Months: 12.9%
- 1 Year: 20.2%
- Year to Date: 8.3%
The market is up 2.3% over the last week, with the Information Technology sector leading the way, up 4.1%. The market is up 20% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading